AMENDMENTS TO THE CLAIMS

1. (currently amended): ~~Derivatives of~~ N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxy-pyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide comprising ~~with~~ at least one covalently bonded acid, and the salts, solvates and prodrugs thereof.

2. (currently amended): The compound of ~~Derivative according to~~ Claim 1 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the acid is covalently bonded via the 3-hydroxypyrrolidine group of the N-methyl-N-[(1 S)-1phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide.

3. (currently amended): The compound of ~~Derivative according to~~ Claim 1 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the acid is a physiologically tolerated acid.

4. (currently amended): The compound of ~~Derivative according to~~ Claim 1 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the acid is selected from the group consisting of carboxylic acids, hydroxycarboxylic acids and inorganic oxygen acids.

5. (currently amended): The compound of ~~Derivative according to~~ Claim 1 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the derivative contains at least one acid function which is capable of salt formation or an acid function which is in the form of a salt.

6. (currently amended): The compound of ~~Derivative according to~~ Claim 1 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the acid is selected from the group consisting of dibasic carboxylic acids, monobasic hydroxycarboxylic acids and dibasic inorganic oxygen acids.

7. (currently amended): A compound of ~~Derivative according to~~ Claim 6 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the monobasic hydroxycarboxylic acid is a sugar acid.

8. (currently amended): The compound of ~~Derivative according to~~ Claim 7 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the sugar acid is glucuronic acid.

9. (currently amended): The compound of ~~Derivative according to~~ Claim 6 or the salt, solvate or prodrug thereof, wherein ~~characterised in that~~ the dibasic inorganic oxygen acid is sulfuric acid.

10. (currently amended): The compound of ~~Derivative according to~~ Claim l, selected from the group consisting of 6-(1-{[(2,2diphenylethanoyl)methylamino]phenylethyl} pyrrolidin-3-yloxy}-3,4,5-tri-hydroxytetrahydropyrarr-2-carboxylic acid, mono-{1[2-(diphenylacetyl-methylamino)-2phenylethyl]pyrrolidin-3-yl} sulfate and N-{2-[(3S)-3-acetoxy-1-pyrrolidinyl]-(1S)-1-phenylethyl}-2,2-diphenyl-N-methylacetamide, and salts, solvates, and prodrugs thereof.

11. (currently amended): The compound of ~~Derivative according to~~ Claim 1 and/or a salt, solvate or prodrug thereof as medicament.

12. (canceled)

13. (currently amended): A method of treating or preventing a disease comprising administering an effective dose of the compound ~~derivative~~, salt, solvate, or prodrug of claim 1 to a subject in need thereof, wherein the disease is selected from the group consisting of a gastrointestinal tract disease, a urinary tract disease, a digestive disorder, and a disease associated with severe pain or conditions of pain.

14. (previously presented): The method of claim 13, wherein the disease is a gastrointestinal tract disease selected from the group consisting of a functional gastrointestinal disease, a functional gastroduodenal disease, a functional intestinal disease, a chronic motility disorder, an inflammatory gastrointestinal tract disease, and a non-inflammatory gastrointestinal tract disease.

15. (previously presented): The method of claim 13, wherein the disease is dyspepsia.

16. (previously presented): The method of claim 13, wherein the disease is irritable bowel syndrome.

17. (previously presented): The method of claim 13, wherein the disease is post-operative ileus.

18. (previously presented): The method of claim 13, wherein the disease is a urinary tract disease selected from the group consisting of an inflammatory and a non-inflammatory urinary tract disease, and irritable bladder syndrome.

19. (currently amended): A method for manufacture of a pharmaceutical composition, comprising:

formulating ingredients of the composition, wherein the ingredients comprise one or more compounds ~~derivatives~~ according to Claim 1, or a salt, solvate, or prodrug thereof, and one or more further compounds selected from excipients[[,]] and adjuvants ~~and pharmaceutical active ingredients which are different from such derivatives~~;

mixing the ingredients to homogeneity; and

preparing the mixture in a form suitable for administration to patients.

20. (currently amended): Pharmaceutical composition, wherein ~~characterised in that~~ it comprises at least one compound, salt, solvate, or prodrug ~~derivative~~ according to Claim 1.

21. (currently amended): Pharmaceutical composition according to Claim 20, wherein ~~characterised in that~~ it comprises at least one further pharmaceutical active ingredient selected from the group consisting of appetite suppressants, vitamins, diuretics, and antiphlogistics.

22. (currently amended): Pharmaceutical composition according to Claim 21, wherein ~~characterised in that~~ the further active ingredient is selected from phenylpropanolamine, cathine, sibutramine, amfepramone, ephedrine and norpseudoephedrine.

23. (currently amended): Process for the preparation of a compound of ~~derivative according to~~ Claim 1 or a salt thereof, in which

a) a compound of the formula II



II

in which

L^1 is H or a metal ion;

b) is reacted with a compound of the formula III

$$R^1\text{-}L^2 \qquad \text{III}$$

in which

L^2 is a leaving group, and

R^1 is selected from substituted or unsubstituted acyl radicals having from 1 to 12 carbon atoms, alkyl radicals derived from polyhydroxymonocarboxylic acids by removal of a hydroxyl group, sulfonic acid groups, phosphonic acid groups and nitro groups or, if

R^1 contains one or more functional groups in addition to the group L^2, a derivative of R^1 which is provided fully or partly with protecting groups,

c) any protecting groups present are cleaved off, if desired the compound of the formula I is isolated, and optionally

d) the resultant compound of the formula I is converted into one of its salts by treatment with an acid or base, and, if desired, the salt is isolated.

24. (currently amended): A pharmaceutical composition comprising the compound of ~~derivative according to~~ claim 10, or a salt, solvate, and prodrug thereof.